Type 2 cytokines, including IL-4 and IL-10, downregulate the tumor-specific immune response by directly suppressing the production of Th1 cytokines, which prevents CTL and NK cell activation and by inhibiting tumor antigen presentation by antigen-presenting cells (18,19). The gene discussed is IL4; the disease is neoplasm.